News Indivior PLC London S.E.

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:04 2025-07-24 EDT			5-day change	1st Jan Change
1,238.00 ^GBX	+1.56%		-.--%	-

01-08	Indivior PLC Provides Earnings Guidance for the Full Year 2026	CI
01-08	Indivior Expects Up to $1.20 Billion in 2026 Net Revenue	MT

01-08	Indivior PLC Provides Earnings Guidance for the Full Year 2026	CI
01-08	Indivior Expects Up to $1.20 Billion in 2026 Net Revenue	MT
01-08	(INDV) Indivior Expects 2026 Revenue Range $1.13B - $1.2B, vs. FactSet Est of $1.19B	MT
01-08	Indivior : Financial Document	PU
01-08	Indivior Provides Full-Year 2026 Financial Guidance and Business Update	GL
12-22	Indivior Joins S&P SmallCap 600 Index	MT
12-22	Indivior Announces Inclusion in the S&P SmallCap 600® Index	PR
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 1000	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P Pharmaceuticals Select Industry Index	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 600 Health Care	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P Composite 1500	CI
12-21	Indivior PLC(NasdaqGS:INDV) added to S&P 600	CI
12-17	New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations	PR
11-20	Indivior Concludes Legacy U.S. Department of Justice Matter	PR
11-19	Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference	PR
11-18	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	AQ
11-14	Camurus Competitor Exits Sweden - Di	FW
11-03	Indivior Presents New Real-World Evidence At AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	CI
11-03	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	PR
25-10-30	Sector Update: Health Care Stocks Rise Late Afternoon	MT
25-10-30	Indivior PLC, Q3 2025 Earnings Call, Oct 30, 2025
25-10-30	Top Midday Gainers	MT
25-10-30	Indivior PLC Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	Indivior Q3 Adjusted Earnings, Revenue Rise; 2025 Revenue Outlook Raised - Shares Up Pre-Bell	MT
25-10-30	Indivior PLC Raises Earnings Guidance for the Year 2025	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Indivior PLC London S.E.

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Filters